Analysts see a role for the amylin agonist thanks to placebo-like tolerability, but Lilly and Novo candidates in the class ...
Edwards and Highlife’s mitral valve replacement systems will receive health technology assessment (HTA) at an EU level via a ...
The German group is hoping to get the green light for the mineralocorticoid receptor antagonist for adults with chronic ...
Investors at the Cell & Gene Meeting on the Mesa expressed concern, though it may be a while before China can become a ...
Arrowhead's severe hypertriglyceridemia (sHTG) filing for Redemplo is the first known entry into the FDA's STAR pilot, an ...
Elixir Medical has won Japanese approval for its DynamX coronary bioadaptor. A launch is planned for mid-2027, while US ...
Having failed a Phase II study for Parkinson’s monotherapy with its first-in-class GPR6 inhibitor, Cerevance will discuss the Phase III data showing benefit with solengepras as an adjunctive therapy ...
Ashwagandha tops consumer search interest across the US and five European markets, according to HBW Insight's Google Trends ...
Malta-based B2B company Adalvo has announced plans to establish a new dedicated GLP-1 business unit focused on advancing ...
A bipartisan Senate bill that would end the Trump Administration’s 340B rebate model pilot and create a national claims ...
European medical device market growth slowed to 1.8% in 2025 from 6.0%, and the number of medtech companies fell for the first time in the report’s history, according to MedTech Europe’s 2026 Facts & ...
The South San Francisco company is developing therapies that target extracellular proteins, and its lead candidate is a food ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results